(Q46702705)

24 December 2017

title

Contrast-enhanced gray-scale harmonic ultrasound in the efficacy assessment of ablation treatments for hepatocellular carcinoma (English)

1 reference

24 December 2017

author

Maurizio Pompili

1

1 reference

24 December 2017

Giovanni Gasbarrini

7

object named as

Giovanni Gasbarrini

1 reference

24 December 2017

author name string

Laura Riccardi

2

1 reference

24 December 2017

Marcello Covino

3

1 reference

24 December 2017

Brunella Barbaro

4

1 reference

24 December 2017

Carmine Di Stasi

5

1 reference

24 December 2017

Ruggero Orefice

6

1 reference

24 December 2017

Gian Ludovico Rapaccini

8

1 reference

24 December 2017

publication date

1 October 2005

1 reference

24 December 2017

published in

Liver International

1 reference

24 December 2017

volume

25

1 reference

24 December 2017

issue

5

1 reference

24 December 2017

page(s)

954-961

1 reference

24 December 2017

Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01135.X

Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01135.X

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01135.X

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01135.X

Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01135.X

Risk factors for intrahepatic recurrence of hepatocellular carcinoma in cirrhotic patients treated by percutaneous ethanol injection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01135.X

Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01135.X

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01135.X

Chemoembolization for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01135.X

Radiofrequency ablation of hepatocellular carcinoma: therapeutic response using contrast-enhanced coded phase-inversion harmonic sonography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01135.X

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01135.X

Hepatocellular carcinoma: diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01135.X

Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01135.X

10.1111/J.1478-3231.2005.01135.X

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017